Trump Psychedelics Order

The order directs federal health agencies to expedite clinical trials for novel psychedelic therapies targeting PTSD and depression.

Trump framed the decision as a historic moment for veterans' mental health and medical innovation.

Shares of psychedelic-focused biotech firms surged following the announcement.

However, some health experts have raised concerns about the safety and regulatory shortcuts that could result from the accelerated process.